Dear Providers,
This email is to inform you that due to the continued RSV activity in the state, we are extending the administration and ordering of pediatric RSV prevention products Nirsevimab (Beyfortus?) and clesrovimab (ENFLONSIA™) for infants and toddlers through April 30, 2026.
RSV monoclonal antibody (mAb) orders may continue to be placed using NCIR. Doses obtained from NCIP are for VFC-eligible children only. Privately purchased stock must be used for fully insured patients. Refer to the RSV NCIR ordering communication for additional ordering instructions.
How to contact us:
For assistance, please contact the NCIP Help Desk by phone at 1.877.USE.NCIR (873-6247)) or by email.
Thank you for your ongoing partnership and dedication to improving immunization outcomes in North Carolina.
In Health,
NC Department of Health and Human Services